 |
Prostate CancerStudy TitlePre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer Prinicipal InvestigatorsStudy NumberN/A Status of TrialOpen Why is this study being done?Mack Roach III, M.D, from the Department of Radiation Oncology, is conducting a review of your chart to determine the effectiveness of your radiation treatment and whether he can identify factors that may affect outcomes. You are being asked to participate in this study because you were treated with radiation therapy for prostate cancer at the University of California at San Francisco, San Francisco General Hospital and San Francisco Veterans Administration Medical Center. ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form Study TitleProspective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy. Prinicipal Investigators
Study NumberRTOG 0526 Status of TrialOpen Why is this study being done?The purpose of this study is to evaluate the safety and effectiveness of brachytherapy (radiation seed implants) as treatment for prostate cancer that has come back in the prostate after external radiotherapy. The study will examine the side effects of the implants as well as the ability of the implants to get rid of the cancer. It is important for you to realize that sometimes when prostate cancer comes back in the prostate after radiation, it may be very slow growing and may not cause you symptoms or problems for years. Sometimes just monitoring your condition and not undergoing repeat treatment is appropriate. The treatment offered in this study may cause side effects. The side effects are discussed in this consent form, and you should read that section carefully and discuss it with your study doctor. ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form Study TitleAdjuvant 3D-CRT/IMRT In Combination With Androgen Suppression And Docetaxel For High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial. Prinicipal Investigators
Study NumberRTOG 0621 Status of TrialOpen Why is this study being done?The purpose of this study is to find out what effects a combination of local (radiation therapy) and systemic (hormonal therapy and chemotherapy) treatments has on the risk of recurrence of your prostate cancer. ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form Study TitleA pilot study of MRI and Spectroscopy Imaging changes with 6-months of dutasteride in patients with symptomatic benign prostatic hypertrophy and low-risk prostate cancer on watchful waiting or requiring neoadjuvant androgen suppression prior to prostate brachytherapy. Prinicipal InvestigatorsStudy NumberRTOG 0534 Status of TrialOpen Why is this study being done?The purpose of this study is to compare the effects, good and/or bad of three treatment methods on participants and their cancer. External beam radiation therapy is one of the standard treatments for men with prostate cancer who have a rising PSA after surgery. Different methods of radiation therapy are used, and it is not known which one is best. Most commonly, the area where the prostate was originally located before being removed (the prostate bed) is treated, without treating the lymph nodes in the pelvis. Prostate cancer can spread to the lymph nodes. There is some evidence in men who have not had surgery that radiotherapy to the pelvic lymph nodes may stop the cancer from spreading under some conditions. Since treating the pelvic lymph nodes can result in increased side effects, the benefit of this method of radiation therapy needs to be tested. Prostate cancer feeds on male hormones, such as testosterone. Drugs that reduce or block testosterone (hormone therapy) can cause some prostate cancer cells to die and others to become sick so that they don’t grow. Some patients treated with a combination of these drugs and radiation have a greater chance of not having the cancer return when compared to men treated with radiation alone. These studies were done in men who did not have surgery. Because hormone therapy can result in increased side effects, the benefit of combining hormone therapy with radiation therapy needs to be tested. There are 3 treatment 1) Patients who receive radiation therapy to the prostate bed only; 2) Patients who receive hormone therapy for 4 to 6 months plus radiation therapy to the prostate bed; 3) Patients who receive hormone therapy for 4 to 6 months plus radiation therapy to the prostate bed and to the pelvic lymph nodes. If you agree to participate in this study, you will receive one of these 3 treatments. ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form Study TitleA Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma Prinicipal InvestigatorsStudy NumberRTOG 0232 Status of TrialOpen Why is this study being done?Dr. Mack Roach and associates from the University of California San Francisco (UCSF) Comprehensive Cancer Center and Dr. Judith Luce and associates from the San Francisco General Hospital (SFGH) are conducting a research study to compare the effects of two investigational treatments in patients with prostate cancer: the effects of placing small radioactive pellets (seeds) inside your prostate (brachytherapy) after external radiation therapy will be compared to the effects of using brachytherapy alone in patients with prostate cancer. You are being asked to participate in this study because you have intermediate risk prostate cancer and combined external beam radiation and brachytherapy or brachytherapy alone are options that has been recommended by your doctor(s). The Radiation Therapy Oncology Group (RTOG) and the National Cancer Institutes (NCI) sponsor this study. The purpose of this study is to compare the effects (good and bad) of two different radiation treatments in patients with prostate cancer. This research is being done to see which treatment is better. In addition, this study will look at biologic factors that may help to predict and treat prostate cancer in the future. This study will also gather information about the effects of the treatment on your sexual function (potency), urinary function, and on your overall quality of life. A cost comparison between the two treatments, including long term cost thereafter, is also planned for participants under Medicare. About 586 patients will participate in this study nationwide. About 27 patients will participate in this study at UCSF and SFGH. All procedures will occur at the clinics at UCSF Comprehensive Cancer Center or SFGH. ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form Study TitleA Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer. Prinicipal InvestigatorsStudy NumberRTOG 0815 Status of TrialOpen Why is this study being done?The purpose of this study is to compare the effects of dose-escalated radiation therapy with or without hormone therapy on your prostate cancer. Prior studies have suggested possible advantages to the administration of hormonal therapy with radiation. However, those studies were performed with radiation techniques that do not match those commonly used in clinical practice today (that is, dose-escalated radiotherapy). Therefore, we will be testing to see if similar benefits for hormonal therapy are seen when used with current radiation therapy techniques. In current clinical practice, either radiation therapy alone (called Arm 1 or Group 1 in this study) or radiation therapy combined with hormone therapy (called Arm 2 or Group 2 in this study) would be considered an acceptable standard treatment for patients with a newly diagnosed intermediate risk prostate cancer. For the purposes of this study design, however, Group 1 is considered the “standard” treatment and Group 2 the “experimental” treatment because Group 2 patients will receive hormonal therapy, which is the treatment under study in this protocol. There are 2 treatment groups in this study: 1) Patients who receive radiation therapy only If you agree to participate in this study, you will receive one of these 2 treatments.ContactMarilyn Robinson, CCRP Download the PDF of full trial description and consent form
|
